Researchers conducted a Phase 3 clinical trial to test a new combination of drugs for people with advanced head and neck cancer that has returned or spread. The study involved 511 patients whose cancer had a specific marker called PD-L1. They compared the standard immunotherapy drug pembrolizumab to pembrolizumab plus an additional drug called lenvatinib.
The trial measured whether tumors shrank, how long patients lived without their cancer getting worse, and overall survival. However, the detailed results for these main goals have not been released to the public yet. We do not know if the combination worked better or if it caused more side effects.
Because the results are not available, it is impossible to draw any conclusions about the treatment's benefits or risks. The study was funded by the company that makes the drugs. For now, patients should know this research is ongoing, and the standard of care has not changed based on this unreported data.
